Targeting β-cell mass in type 2 diabetes:: Promise and limitations of new drugs based on incretins

被引：89

作者：

Salehi, Marzieh ^{[1
]}

Aulinger, Benedikt A. ^{[1
]}

D'Alessio, David A. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Med, Div Endocrinol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA

来源：

ENDOCRINE REVIEWS | 2008年 / 29卷 / 03期

关键词：

D O I：

10.1210/er.2007-0031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

引用

页码：367 / 379

页数：13

共 163 条

[21] Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation [J].

Buteau, J ;

Foisy, S ;

Rhodes, CJ ;

Carpenter, L ;

Biden, TJ ;

Prentki, M .

DIABETES, 2001, 50 (10) :2237-2243

[22] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].

Butler, AE ;

Janson, J ;

Bonner-Weir, S ;

Ritzel, R ;

Rizza, RA ;

Butler, PC .

DIABETES, 2003, 52 (01) :102-110

[23] The replication of β cells in normal physiology, in disease and for therapy [J].

Butler, Peter C. ;

Meier, Juris J. ;

Butler, Alexandra E. ;

Bhushan, Anil .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (11) :758-768

[24] Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function [J].

Byrne, MM ;

Sturis, J ;

Sobel, RJ ;

Polonsky, KS .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 270 (04) :E572-E579

[25] The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose [J].

Chang, AM ;

Jakobsen, G ;

Sturis, J ;

Smith, MJ ;

Bloem, CJ ;

An, B ;

Galecki, A ;

Halter, JB .

DIABETES, 2003, 52 (07) :1786-1791

[26] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

[27] Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance [J].

Conarello, SL ;

Li, ZH ;

Ronan, J ;

Roy, RS ;

Zhu, L ;

Jiang, GQ ;

Liu, F ;

Woods, J ;

Zycband, E ;

Moller, DE ;

Thornberry, NA ;

Zhang, BB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) :6825-6830

[28] GUT HORMONES AND DIABETES-MELLITUS [J].

CREUTZFELDT, W ;

NAUCK, M .

DIABETES-METABOLISM REVIEWS, 1992, 8 (02) :149-177

[29] NEW DEVELOPMENTS IN THE INCRETIN CONCEPT [J].

CREUTZFELDT, W ;

EBERT, R .

DIABETOLOGIA, 1985, 28 (08) :565-573

[30] GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL [J].

DALESSIO, DA ;

KAHN, SE ;

LEUSNER, CR ;

ENSINCK, JW .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2263-2266

← 1 2 3 4 5 6 7 8 9 10 →